Merck & Co., Inc. logo
Merck & Co., Inc. (MRK)
Compare

Merck & Co., Inc. (MRK) Debt to Assets Ratio: 0.37%

The debt to assets ratio for Merck & Co., Inc. (MRK) is 0.37% as of Tuesday, June 9, 2026.

MRK Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

0.37%

MRK Competitors' Debt to Assets Ratio

NAMEMARKET CAPDEBT TO ASSETS RATIO
Merck & Co., Inc. (MRK)0.37%
UnitedHealth Group Incorporated (UNH)$375.06B0.25%
AbbVie Inc. (ABBV)$398.27B0.52%
Amgen Inc. (AMGN)$185.96B0.60%
Thermo Fisher Scientific Inc. (TMO)$183.61B0.37%
Abbott Laboratories (ABT)$158.94B0.17%
Gilead Sciences, Inc. (GILD)$155.82B0.42%
Intuitive Surgical, Inc. (ISRG)$151.09B0.01%
Pfizer Inc. (PFE)$146.48B0.32%
Danaher Corporation (DHR)$133.37B0.22%

Leverage Ratios Comparison

Debt/Assets

0.4%

Debt/Equity

0.96

Current Ratio

1.54

Interest Coverage

17.3x

Formula: Debt/Assets = Total Debt / Total Assets × 100

Debt/Assets vs Debt/Equity:

  • Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
  • Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
  • Both measure leverage but from different perspectives

Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.

Merck & Co., Inc. Debt to Assets Ratio Formula & Definition

Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Merck & Co., Inc. Debt to Assets Ratio FAQ

What is the debt to assets ratio for Merck & Co., Inc. (MRK)?
The debt to assets ratio for MRK stock is 0.37%.

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Rahway, NJ
73,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert Davis